PegIFN Alpha-2a Therapy Reduces Relapse Risk after NUC Discontinuation in HBeAg-Negative Chronic Hepatitis B: Insights from a Randomized Controlled Trial
Switching from nucleo(s)tide analogues to pegylated interferon alpha-2a significantly lowers virological relapse and boosts HBsAg clearance in HBeAg-negative chronic hepatitis B patients after treatment cessation.